
## Alison P Galvani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3381828/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet, The, 2016, 388, 1089-1102.	13.7	458
2	Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9122-9126.	7.1	441
3	Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7504-7509.	7.1	429
4	The implications of silent transmission for the control of COVID-19 outbreaks. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17513-17515.	7.1	419
5	The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clinical Infectious Diseases, 2021, 73, 2257-2264.	5.8	376
6	Optimizing Influenza Vaccine Distribution. Science, 2009, 325, 1705-1708.	12.6	370
7	Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	345
8	Strategies for containing Ebola in West Africa. Science, 2014, 346, 991-995.	12.6	244
9	Social Factors in Epidemiology. Science, 2013, 342, 47-49.	12.6	188
10	Nine challenges in incorporating the dynamics of behaviour in infectious diseases models. Epidemics, 2015, 10, 21-25.	3.0	174
11	Optimal COVID-19 quarantine and testing strategies. Nature Communications, 2021, 12, 356.	12.8	164
12	Dynamics and control of Ebola virus transmission in Montserrado, Liberia: a mathematical modelling analysis. Lancet Infectious Diseases, The, 2014, 14, 1189-1195.	9.1	154
13	The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe, The, 2021, 2, e666-e675.	7.3	147
14	Projecting demand for critical care beds during COVID-19 outbreaks in Canada. Cmaj, 2020, 192, E489-E496.	2.0	132
15	Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biology, 2021, 19, e3001211.	5.6	111
16	Ethical Alternatives to Experiments with Novel Potential Pandemic Pathogens. PLoS Medicine, 2014, 11, e1001646.	8.4	106
17	Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. Lancet Public Health, The, 2021, 6, e184-e191.	10.0	106
18	Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 398, 2186-2192.	13.7	106

#	Article	IF	CITATIONS
19	Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. EClinicalMedicine, 2021, 35, 100865.	7.1	100
20	Impact of Social Distancing Measures on Coronavirus Disease Healthcare Demand, Central Texas, USA. Emerging Infectious Diseases, 2020, 26, 2361-2369.	4.3	93
21	Effect of Ebola Progression on Transmission and Control in Liberia. Annals of Internal Medicine, 2015, 162, 11-17.	3.9	83
22	Human–environment interactions in population and ecosystem health. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14502-14506.	7.1	83
23	The global burden of HIV and prospects for control. Lancet HIV,the, 2019, 6, e809-e811.	4.7	81
24	Social contacts, vaccination decisions and influenza in Japan. Journal of Epidemiology and Community Health, 2016, 70, 162-167.	3.7	77
25	Reassessment of HIV-1 Acute Phase Infectivity: Accounting for Heterogeneity and Study Design with Simulated Cohorts. PLoS Medicine, 2015, 12, e1001801.	8.4	75
26	The exacerbation of Ebola outbreaks by conflict in the Democratic Republic of the Congo. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24366-24372.	7.1	72
27	Cost-Effectiveness of Canine Vaccination to Prevent Human Rabies in Rural Tanzania. Annals of Internal Medicine, 2014, 160, 91-100.	3.9	71
28	Vaccination strategies against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13239-13244.	7.1	70
29	Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. Cmaj, 2020, 192, E666-E670.	2.0	65
30	Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. Lancet Infectious Diseases, The, 2015, 15, 703-710.	9.1	64
31	One Health approach to cost-effective rabies control in India. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14574-14581.	7.1	63
32	Improving the prognosis of health care in the USA. Lancet, The, 2020, 395, 524-533.	13.7	63
33	Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4017-4022.	7.1	62
34	Direct and Indirect Effects of Rotavirus Vaccination: Comparing Predictions from Transmission Dynamic Models. PLoS ONE, 2012, 7, e42320.	2.5	60
35	Epidemiological and Viral Genomic Sequence Analysis of the 2014 Ebola Outbreak Reveals Clustered Transmission. Clinical Infectious Diseases, 2015, 60, 1079-1082.	5.8	59
36	Dynamic Models of Infectious Disease Transmission in Prisons and the General Population. Epidemiologic Reviews, 2018, 40, 40-57.	3.5	57

#	Article	IF	CITATIONS
37	A Cost-Effectiveness Tool for Informing Policies on Zika Virus Control. PLoS Neglected Tropical Diseases, 2016, 10, e0004743.	3.0	56
38	Stimulating Influenza Vaccination via Prosocial Motives. PLoS ONE, 2016, 11, e0159780.	2.5	53
39	Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA. Lancet Infectious Diseases, The, 2020, 20, 1123-1125.	9.1	53
40	Uncoupling vaccination from politics: a call to action. Lancet, The, 2021, 398, 1211-1212.	13.7	53
41	Modelling control of Schistosoma haematobium infection: predictions of the long-term impact of mass drug administration in Africa. Parasites and Vectors, 2015, 8, 529.	2.5	50
42	The potential economic burden of Zika in the continental United States. PLoS Neglected Tropical Diseases, 2017, 11, e0005531.	3.0	49
43	Quantifying Transmission of <i>Clostridium difficile</i> within and outside Healthcare Settings. Emerging Infectious Diseases, 2016, 22, 608-616.	4.3	48
44	Optimizing the impact of low-efficacy influenza vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5151-5156.	7.1	48
45	The impact of mask-wearing and shelter-in-place on COVID-19 outbreaks in the United States. International Journal of Infectious Diseases, 2020, 101, 334-341.	3.3	48
46	Resolving the apparent transmission paradox of African sleeping sickness. PLoS Biology, 2019, 17, e3000105.	5.6	47
47	The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	47
48	National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5107-5112.	7.1	46
49	Respiratory virus transmission dynamics determine timing of asthma exacerbation peaks: Evidence from a population-level model. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2194-2199.	7.1	46
50	Disease Surveillance on Complex Social Networks. PLoS Computational Biology, 2016, 12, e1004928.	3.2	46
51	Defining control of HIV epidemics. Lancet HIV,the, 2018, 5, e667-e670.	4.7	44
52	Interrupting Ebola Transmission in Liberia Through Community-Based Initiatives. Annals of Internal Medicine, 2016, 164, 367.	3.9	42
53	HIV and <i>Schistosoma haematobium</i> prevalences correlate in subâ€Saharan Africa. Tropical Medicine and International Health, 2013, 18, 1174-1179.	2.3	41
54	Evaluating long-term effectiveness of sleeping sickness control measures in Guinea. Parasites and Vectors, 2015, 8, 550.	2.5	41

#	Article	IF	CITATIONS
55	Assessing real-time Zika risk in the United States. BMC Infectious Diseases, 2017, 17, 284.	2.9	41
56	Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. Preventive Medicine, 2021, 148, 106564.	3.4	40
57	Efficacy and Optimization of Palivizumab Injection Regimens Against Respiratory Syncytial Virus Infection. JAMA Pediatrics, 2015, 169, 341.	6.2	39
58	Under-reporting and case fatality estimates for emerging epidemics. BMJ, The, 2015, 350, h1115-h1115.	6.0	38
59	Ebola vaccination in the Democratic Republic of the Congo. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10178-10183.	7.1	38
60	Optimizing age-specific vaccination. Science, 2021, 371, 890-891.	12.6	38
61	Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic. JAMA Network Open, 2022, 5, e2142725.	5.9	38
62	Underestimation of the global burden of schistosomiasis. Lancet, The, 2018, 391, 307-308.	13.7	37
63	Assessing Strategies Against Gambiense Sleeping Sickness Through Mathematical Modeling. Clinical Infectious Diseases, 2018, 66, S286-S292.	5.8	37
64	Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. Lancet HIV,the, 2018, 5, e498-e505.	4.7	37
65	Modeling mitigation of influenza epidemics by baloxavir. Nature Communications, 2020, 11, 2750.	12.8	36
66	Cost-effectiveness of a community-based intervention for reducing the transmission of <i>Schistosoma haematobium</i> and HIV in Africa. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7952-7957.	7.1	35
67	Modelling microbial infection to address global health challenges. Nature Microbiology, 2019, 4, 1612-1619.	13.3	34
68	Buyer beware: inflated claims of sensitivity for rapid COVID-19 tests. Lancet, The, 2021, 397, 24-25.	13.7	34
69	The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission. PLoS Neglected Tropical Diseases, 2018, 12, e0006809.	3.0	32
70	Harnessing Case Isolation and Ring Vaccination to Control Ebola. PLoS Neglected Tropical Diseases, 2015, 9, e0003794.	3.0	31
71	Cross-country evidence on the association between contact tracing and COVID-19 case fatality rates. Scientific Reports, 2021, 11, 2145.	3.3	31
72	Pregnancy outcomes in Liberian women who conceived after recovery from Ebola virus disease. The Lancet Global Health, 2016, 4, e678-e679.	6.3	30

#	Article	IF	CITATIONS
73	Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. The Lancet Regional Health Americas, 2022, 5, 100085.	2.6	30
74	Probabilistic uncertainty analysis of epidemiological modeling to guide public health intervention policy. Epidemics, 2014, 6, 37-45.	3.0	29
75	Quantitative assessment of the impact of partially protective anti-schistosomiasis vaccines. PLoS Neglected Tropical Diseases, 2017, 11, e0005544.	3.0	29
76	Spatial and Temporal Clustering of Chikungunya Virus Transmission in Dominica. PLoS Neglected Tropical Diseases, 2015, 9, e0003977.	3.0	27
77	Implementation of Syringe Services Programs to Prevent Rapid Human Immunodeficiency Virus Transmission in Rural Counties in the United States: A Modeling Study. Clinical Infectious Diseases, 2020, 70, 1096-1102.	5.8	27
78	Future epidemiological and economic impacts of universal influenza vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20786-20792.	7.1	26
79	Racial disparities in COVID-19 mortality across Michigan, United States. EClinicalMedicine, 2021, 33, 100761.	7.1	26
80	Impact of Schistosoma mansoni on Malaria Transmission in Sub-Saharan Africa. PLoS Neglected Tropical Diseases, 2014, 8, e3234.	3.0	25
81	COVID-19 on the African continent. Lancet Infectious Diseases, The, 2020, 20, 1368-1370.	9.1	25
82	Spatial heterogeneity in projected leprosy trends in India. Parasites and Vectors, 2015, 8, 542.	2.5	23
83	Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC). PLoS Neglected Tropical Diseases, 2020, 14, e0007976.	3.0	23
84	Epidemiological and Economic Effects of Priming With the Whole-Cell <i>Bordetella pertussis</i> Vaccine. JAMA Pediatrics, 2016, 170, 459.	6.2	22
85	Simulated Identification of Silent COVID-19 Infections Among Children and Estimated Future Infection Rates With Vaccination. JAMA Network Open, 2021, 4, e217097.	5.9	22
86	Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	22
87	Evaluating the potential impact of mass praziquantel administration for HIV prevention in Schistosoma haematobium high-risk communities. Epidemics, 2014, 7, 22-27.	3.0	21
88	Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa. PLoS ONE, 2015, 10, e0126267.	2.5	21
89	Determinants of Human African Trypanosomiasis Elimination via Paratransgenesis. PLoS Neglected Tropical Diseases, 2016, 10, e0004465.	3.0	21
90	Cellular Superspreaders: An Epidemiological Perspective on HIV Infection inside the Body. PLoS Pathogens, 2014, 10, e1004092.	4.7	20

#	Article	IF	CITATIONS
91	Evaluating the effectiveness of localized control strategies to curtail chikungunya. Scientific Reports, 2016, 6, 23997.	3.3	20
92	Population Immunity Against COVID-19 in the United States. Annals of Internal Medicine, 2021, 174, 1586-1591.	3.9	20
93	Routine saliva testing for the identification of silent coronavirus disease 2019 (COVID-19) in healthcare workers. Infection Control and Hospital Epidemiology, 2021, 42, 1189-1193.	1.8	20
94	Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS ONE, 2016, 11, e0165614.	2.5	20
95	Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study. Lancet Regional Health - Europe, The, 2022, 14, 100304.	5.6	20
96	Characterizing risk of Ebola transmission based on frequency and type of case–contact exposures. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160301.	4.0	18
97	Global elimination of lymphatic filariasis. Lancet Infectious Diseases, The, 2017, 17, 358-359.	9.1	17
98	The case for replacing live oral polio vaccine with inactivated vaccine in the Americas. Lancet, The, 2020, 395, 1163-1166.	13.7	17
99	Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. Vaccine, 2021, 39, 5037-5045.	3.8	17
100	Incentives for COVID-19 vaccination. The Lancet Regional Health Americas, 2022, 8, 100205.	2.6	17
101	Prosocial polio vaccination in Israel. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13138-13144.	7.1	16
102	Are the London Declaration's 2020 goals sufficient to control Chagas disease?: Modeling scenarios for the Yucatan Peninsula. PLoS Neglected Tropical Diseases, 2018, 12, e0006337.	3.0	16
103	Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas. Lancet Infectious Diseases, The, 2021, 21, 1493-1494.	9.1	16
104	COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in n northeastern and southern regions of the USA. The Lancet Regional Health Americas, 2022, 6, 100147.	2.6	16
105	An Innovative Influenza Vaccination Policy: Targeting Last Season's Patients. PLoS Computational Biology, 2014, 10, e1003643.	3.2	15
106	Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel. Vaccine, 2014, 32, 4198-4205.	3.8	15
107	Using Community-Level Prevalence of Loa loa Infection to Predict the Proportion of Highly-Infected Individuals: Statistical Modelling to Support Lymphatic Filariasis and Onchocerciasis Elimination Programs. PLoS Neglected Tropical Diseases, 2016, 10, e0005157.	3.0	15
108	Forecasting the new case detection rate of leprosy in four states of Brazil: A comparison of modelling approaches. Epidemics, 2017, 18, 92-100.	3.0	15

#	Article	IF	CITATIONS
109	The imperative for universal healthcare to curtail the COVID-19 outbreak in the USA. EClinicalMedicine, 2020, 23, 100380.	7.1	15
110	Lessons learned during COVID-19: Building critical care/ICU capacity for resource limited countries with complex emergencies in the World Health Organization Eastern Mediterranean Region. Journal of Global Health, 2021, 11, 03083.	2.7	15
111	Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program in the First 22 Months of Implementation. JAMA Network Open, 2020, 3, e2030427.	5.9	15
112	Comparison and validation of two computational models of Chagas disease: A thirty year perspective from Venezuela. Epidemics, 2017, 18, 81-91.	3.0	14
113	Policy Lessons From Quantitative Modeling of Leprosy. Clinical Infectious Diseases, 2018, 66, S281-S285.	5.8	14
114	Comparing the Impact of Artemisinin-Based Combination Therapies on Malaria Transmission in Sub-Saharan Africa. American Journal of Tropical Medicine and Hygiene, 2015, 92, 555-560.	1.4	13
115	Cross-Cultural Household Influence on Vaccination Decisions. Medical Decision Making, 2016, 36, 844-853.	2.4	13
116	Comparative analyses of eighteen rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation. Communications Medicine, 2022, 2, .	4.2	13
117	Disease elimination and re-emergence in differential-equation models. Journal of Theoretical Biology, 2015, 387, 174-180.	1.7	12
118	Harnessing synergies at the interface of public health and the security sector. Lancet, The, 2019, 393, 207-209.	13.7	12
119	Can the USA return to pre-COVID-19 normal by July 4?. Lancet Infectious Diseases, The, 2021, 21, 1073-1074.	9.1	12
120	Strategies to prevent future Ebola epidemics. Lancet, The, 2015, 386, 131.	13.7	11
121	Evaluating Vaccination Strategies for Zika Virus in the Americas. Annals of Internal Medicine, 2018, 168, 621-630.	3.9	11
122	Importance of non-pharmaceutical interventions in the COVID-19 vaccination era: A case study of the Seychelles. Journal of Global Health, 2021, 11, 03104.	2.7	11
123	Retrospective Analysis of the 2014–2015 Ebola Epidemic in Liberia. American Journal of Tropical Medicine and Hygiene, 2016, 94, 833-839.	1.4	10
124	Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. Proceedings of the Royal Society B: Biological Sciences, 2016, 283, 20161211.	2.6	10
125	Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study. The Lancet Regional Health Americas, 2022, 8, 100182.	2.6	10
126	Philippine drug war and impending public health crisis. Lancet, The, 2016, 388, 2870.	13.7	9

#	Article	IF	CITATIONS
127	Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US. Vaccine, 2016, 34, 225-229.	3.8	9
128	The Unrecognized Death Toll of COVID-19 in the United States. The Lancet Regional Health Americas, 2021, 1, 100033.	2.6	9
129	Cost-Effectiveness of Rotavirus Vaccination in France—Accounting for Indirect Protection. Value in Health, 2016, 19, 811-819.	0.3	8
130	Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee. Lancet, The, 2017, 390, 2410-2412.	13.7	8
131	What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks?. Journal of Infectious Diseases, 2019, 220, 920-931.	4.0	8
132	Spatio-temporal dynamics of measles outbreaks in Cameroon. Annals of Epidemiology, 2020, 42, 64-72.e3.	1.9	8
133	The interplay between COVID-19 restrictions and vaccination. Lancet Infectious Diseases, The, 2021, 21, 1053-1054.	9.1	8
134	Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings. PLoS Neglected Tropical Diseases, 2016, 10, e0004802.	3.0	8
135	Impact of One-Health framework on vaccination cost-effectiveness: A case study of rabies in Ethiopia. One Health, 2019, 8, 100103.	3.4	7
136	The impact of vector migration on the effectiveness of strategies to control gambiense human African trypanosomiasis. PLoS Neglected Tropical Diseases, 2019, 13, e0007903.	3.0	7
137	The burden of childhood pneumonia in India and prospects for control. The Lancet Child and Adolescent Health, 2020, 4, 643-645.	5.6	7
138	Exacerbation of COVID-19 mortality by the fragmented United States healthcare system: A retrospective observational study. The Lancet Regional Health Americas, 2022, 12, 100264.	2.6	7
139	Impact of bed capacity on spatiotemporal shifts in Ebola transmission. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14125-14126.	7.1	6
140	Strategies for Trypanosoma brucei gambiense elimination. The Lancet Global Health, 2017, 5, e10-e11.	6.3	6
141	Modelling the impact of antimalarial quality on the transmission of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Infectious Disease Modelling, 2017, 2, 161-187.	1.9	4
142	Curbing the 2019 Samoa measles outbreak. Lancet Infectious Diseases, The, 2020, 20, 287-288.	9.1	4
143	Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy. PLoS Computational Biology, 2021, 17, e1009031.	3.2	4
144	Cost-effectiveness of next-generation vaccines: The case of pertussis. Vaccine, 2016, 34, 3405-3411.	3.8	3

#	Article	IF	CITATIONS
145	Cost-effectiveness of transitional US plans for universal health care. Lancet, The, 2020, 395, 1692-1693.	13.7	3
146	Network structure and rapid HIV transmission among people who inject drugs: A simulation-based analysis. Epidemics, 2021, 34, 100426.	3.0	3
147	Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy. BMC Public Health, 2021, 21, 1543.	2.9	3
148	Large numbers cause magnitude neglect: The case of government expenditures. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	3
149	Public health impact of disease–behavior dynamics. Physics of Life Reviews, 2015, 15, 55-56.	2.8	2
150	Quantifying risk factors to guide progress towards leprosy elimination. The Lancet Global Health, 2019, 7, e1154-e1155.	6.3	2
151	Fund global health: Save lives and money. Science, 2017, 356, 1018-1019.	12.6	1
152	California Universal Health Care Bill: an economic stimulus and life-saving proposal. Lancet, The, 2017, 390, 2012-2014.	13.7	1
153	The Challenge of Vanquishing HIV for the Next Generation—Facing the Future. JAMA Pediatrics, 2018, 172, 609.	6.2	1
154	The effect of Medicare for All on rural hospitals – Authors' reply. Lancet, The, 2020, 396, 1392-1393.	13.7	1
155	Universal health care needed to end HIV epidemic in the USA. Lancet HIV,the, 2021, 8, e63-e64.	4.7	1
156	Metrics and benchmarks for HIV transition – Authors' reply. Lancet HIV,the, 2019, 6, e150.	4.7	0